The landscape of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has expanded considerably in the last several years, owing to the launches of three oral therapies, namely first-to-market Gilenya (Novartis/Mitsubishi Tanabe Pharma’s fingolimod), Aubagio (Genzyme’s teriflunomide), and, most recently, Tecfidera (Biogen Idec’s dimethyl fumarate [formerly BG-12]). The MS market is poised for further growth with the forecasted launch of at least five additional DMTs over the next three years, including two alternative formulations of existing DMTs—a three-times-weekly (3TW), high-volume version of Copaxone (Teva’s Copaxone 40 mg/mL) and a subcutaneously administered pegylated version of IFN-β-1a (Biogen Idec’s Plegridy)—as well as three novel DMTs, Lemtrada (Genzyme/Bayer HealthCare’s alemtuzumab), daclizumab high yield process (HYP) (Biogen Idec/AbbVie), and ocrelizumab (Roche/Genentech). With an influx of new DMTs and accompanying growth in treatment costs, prescribers’ choice of therapy and payers’ decisions about formulary inclusion/coverage will become increasingly complex as developers strive to differentiate new entrants within the evolving treatment algorithm and to position themselves as favorably as possible on payers’ formularies.
In this report, we surveyed 105 neurologists, and 30 managed care organization (MCO) pharmacy and medical directors to assess their attitudes, expectations, receptivity, and reservations regarding currently marketed and late-stage emerging DMTs for the treatment of MS.
This U.S. Physician & Payer Forum report contains insights from a survey of 105 neurologists and 30 MCO pharmacy/medical directors regarding physician and payer dynamics that affect prescribing practices for the treatment of MS in the United States. In this report, we explore the use, reception, and formulary status of key current and recently launched MS DMTs by neurologists and MCO directors, and gauge physician and payer outlook on five late-stage emerging DMTs. By understanding the attitudes and expectations of prescribers and payers toward current, recently approved, and emerging MS DMTs, stakeholders can gain an understanding of the complex and changing prescribing and reimbursement climate for MS.
Markets covered: United States.
Primary research: Online survey of 105 neurologists and 30 MCO pharmacy or medical directors.
Epidemiology: 2012, 2017, and 2022 diagnosed prevalent cases of relapsing-remitting MS (RR-MS) and chronic-progressive MS (CP-MS, which encompasses secondary progressive MS [SP-MS] and primary progressive MS [PP-MS]).
Population segments: Where appropriate, our data and analyses are segmented by the following key MS subtypes: clinically isolated syndrome (CIS), RR-MS, SP-MS, and PP-MS.